“…In our study, 2.5 mg/kg of DBcAMP remarkably increased plasma 1,25(OH)2D in a patient with PHP of Type I (Case 9) with a reciprocal decrease in plasma 24,25-(OH)2D. Relating to these findings, some workers demonstrated that CAMP or DBcAMP reproduced the stimulating effect of PTH on 1,25(OH)D2 production by in vitro or in vivo animal experiments (Rasmussen et al 1972;Larkins et al 1974;Horiuchi et al 1977). Taken together, it is suggested that DBcAMP stimulates 1a-hydroxylase activity and inhibits 24-hydroxylase activity in Type I PHP, and that the mechanism of production or inhibition of vitamin D metabolites after CAMP producing system is not impaired.…”